SciMar Ltd. is a private Manitoba company founded on the discovery of the mechanisim of pre-diabetic insulin resistance (AMIS Syndrome) and resultant pathologies including:
Its mechanistic-targeted disease managment approach has led to the development of novel solutions for diagnostics, prevention, and treatment that will revolutionize this major market.
SciMar Ltd. is driven by the exciting potential of breakthrough science: the unparalleled health benefits for consumers; the tremendous business opportunities; and the chance to make a positive impact in the world.
SciMar's scientific headquarters, located in the Lautt lab at the University of Manitoba, is the hub of a team of world-class contributors and collaborators from several continents. Its people and its commitment to its core values of Innovation, Integrity, and Value set it apart and drives it success.
member
Medicago, a Quebec-based biopharmaceutical company, said it has produced a virus-like particle of the novel coronavirus, a first step to producing a vaccine.The isolated particle will now undergo pre-clinical safety and efficacy.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.